Author

Lauren J. Schwimmer

ORCID 0009-0004-3449-8537Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Richard C. YuiD· 2 shared Swastik Sen· 2 shared Andrea G. HohmanniD· 1 shared Carlos Henrique Alves JesusiD· 1 shared Dipankar BhattacharyaiD· 1 shared Emily Fender SizemoreiD· 1 shared Gopireddy Raghavender ReddyiD· 1 shared Jonah L. WirtiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Richard C. YuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases

Raghavender Reddy Gopireddy, Dipankar Bhattacharya, Swastik Sen, Monica A. Schwartz, Scott L. Friedman, Richard C. Yu, Toshi Takeuchi, Lauren J. Schwimmer

This paper introduces two novel CB2-specific agonist antibodies that reduce macrophage activation and fibrosis in vitro and an ex vivo liver model.

Molecular Pharmacology · Jan 14, 2026Peer-reviewedPharmacology & Toxicology

CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy

Carlos Henrique Alves Jesus, Gopireddy Raghavender Reddy, Emily Fender Sizemore, Jonah L. Wirt, Swastik Sen, Richard C. Yu, Toshihiko Takeuchi, Lauren J. Schwimmer, Andrea G. Hohmann

This study evaluates CB2-specific antibody agonists for treating chemotherapy-induced peripheral neuropathy, showing pain relief without tolerance or off-target effects.

bioRxiv · Nov 26, 2025 · PreprintNeuroscience